1. Home
  2. IIPR vs MESO Comparison

IIPR vs MESO Comparison

Compare IIPR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IIPR
  • MESO
  • Stock Information
  • Founded
  • IIPR 2016
  • MESO 2004
  • Country
  • IIPR United States
  • MESO Australia
  • Employees
  • IIPR N/A
  • MESO N/A
  • Industry
  • IIPR Real Estate
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IIPR Finance
  • MESO Health Care
  • Exchange
  • IIPR Nasdaq
  • MESO Nasdaq
  • Market Cap
  • IIPR 1.8B
  • MESO 2.0B
  • IPO Year
  • IIPR 2016
  • MESO N/A
  • Fundamental
  • Price
  • IIPR $68.03
  • MESO $17.30
  • Analyst Decision
  • IIPR Buy
  • MESO Buy
  • Analyst Count
  • IIPR 7
  • MESO 4
  • Target Price
  • IIPR $113.20
  • MESO $13.50
  • AVG Volume (30 Days)
  • IIPR 554.5K
  • MESO 849.1K
  • Earning Date
  • IIPR 02-24-2025
  • MESO 02-28-2025
  • Dividend Yield
  • IIPR 11.16%
  • MESO N/A
  • EPS Growth
  • IIPR N/A
  • MESO N/A
  • EPS
  • IIPR 5.61
  • MESO N/A
  • Revenue
  • IIPR $310,929,000.00
  • MESO $5,902,000.00
  • Revenue This Year
  • IIPR N/A
  • MESO $65.99
  • Revenue Next Year
  • IIPR N/A
  • MESO $425.77
  • P/E Ratio
  • IIPR $12.15
  • MESO N/A
  • Revenue Growth
  • IIPR 3.36
  • MESO N/A
  • 52 Week Low
  • IIPR $62.45
  • MESO $1.72
  • 52 Week High
  • IIPR $138.35
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • IIPR 27.60
  • MESO 56.09
  • Support Level
  • IIPR $62.45
  • MESO $15.70
  • Resistance Level
  • IIPR $69.02
  • MESO $17.67
  • Average True Range (ATR)
  • IIPR 2.01
  • MESO 1.40
  • MACD
  • IIPR 1.34
  • MESO -0.43
  • Stochastic Oscillator
  • IIPR 69.92
  • MESO 25.40

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: